Abstract
Using clonogenic survival assays, we demonstrated that a new platinum-acridine hybrid agent, PT-ACRAMTU, is cytotoxic in SNB19 and U87MG glioblastoma cells at low-micromolar concentrations. PT-ACRAMTU is more cytotoxic than ACRAMTU (the platinum-free acridine), acts in a time and dose dependent manner, and appears to generate an apoptotic response in both cell lines on the basis of increased caspase-3 activity.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acridines / chemistry*
-
Acridines / pharmacology
-
Acridines / toxicity
-
Animals
-
Carmustine / pharmacology*
-
Carmustine / toxicity
-
Caspase 3
-
Caspases / metabolism
-
Cell Line
-
Cisplatin / pharmacology*
-
Cisplatin / toxicity
-
Cross-Linking Reagents / pharmacology
-
Cross-Linking Reagents / toxicity
-
Dose-Response Relationship, Drug
-
Drug Screening Assays, Antitumor
-
Glioblastoma / pathology
-
Inhibitory Concentration 50
-
Organoplatinum Compounds / pharmacology
-
Organoplatinum Compounds / toxicity
-
Platinum / chemistry*
-
Platinum / pharmacology
-
Platinum / toxicity
Substances
-
Acridines
-
Cross-Linking Reagents
-
Organoplatinum Compounds
-
Platinum
-
Caspase 3
-
Caspases
-
Cisplatin
-
Carmustine